S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

$0.84
+0.09 (+11.98%)
(As of 02/27/2024 ET)
Today's Range
$0.75
$0.85
50-Day Range
$0.67
$0.84
52-Week Range
$0.55
$1.45
Volume
155,830 shs
Average Volume
53,695 shs
Market Capitalization
$17.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Onconova Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,207.7% Upside
$11.00 Price Target
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Onconova Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Medical Sector

522nd out of 944 stocks

Pharmaceutical Preparations Industry

221st out of 406 stocks


ONTX stock logo

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX Stock Price History

ONTX Stock News Headlines

Onconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.com
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (ONTX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q2 2023 Onconova Therapeutics Inc Earnings Call
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/28/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+1,207.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,960,000.00
Net Margins
-8,930.97%
Pretax Margin
-8,930.97%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$1.35 per share

Miscellaneous

Free Float
20,310,000
Market Cap
$17.67 million
Optionable
Optionable
Beta
1.33
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














ONTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

What is Onconova Therapeutics' stock price target for 2024?

1 brokerages have issued 1 year price targets for Onconova Therapeutics' stock. Their ONTX share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 1,207.7% from the stock's current price.
View analysts price targets for ONTX
or view top-rated stocks among Wall Street analysts.

How have ONTX shares performed in 2024?

Onconova Therapeutics' stock was trading at $0.7456 on January 1st, 2024. Since then, ONTX shares have increased by 12.8% and is now trading at $0.8412.
View the best growth stocks for 2024 here
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 95.43% and a negative net margin of 8,930.97%. During the same period in the previous year, the company earned ($0.45) earnings per share.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, James J Marino and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONTX) was last updated on 2/28/2024 by MarketBeat.com Staff